Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 7/20 | 0.53 |
| ▸ | MAOB | P27338 | 7/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30461144 | 1.00 | NPC1 (0.55) | NPC1RAB9ATDP1MAOAMAOB | |
| SCHEMBL30622749 | 1.00 | NPC1 (0.55) | NPC1RAB9ATDP1MAOAMAOB | |
| SCHEMBL4748638 | 1.00 | NPC1 (0.55) | NPC1RAB9ATDP1MAOAMAOB | |
| SCHEMBL1279355 | 0.95 | NPC1 (0.59) | NPC1RAB9ATDP1MAOAMAOB | |
| SCHEMBL30855377 | 0.95 | NPC1 (0.59) | NPC1RAB9ATDP1MAOAMAOB | |
| SCHEMBL15426822 | 0.92 | MAOA (0.60) | NPC1RAB9ATDP1MAOAMAOB | |
| SCHEMBL22181586 | 0.92 | MAOA (0.60) | NPC1RAB9ATDP1MAOAMAOB | |
| SCHEMBL17364458 | 0.89 | NPC1 (0.61) | NPC1RAB9ATDP1MAOAMAOB | |
| SCHEMBL5001878 | 0.89 | NPC1 (0.54) | NPC1RAB9ATDP1MAOAMAOB | |
| SCHEMBL695627 | 0.87 | NPC1 (0.57) | NPC1RAB9ATDP1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116969904-A | Compounds useful as autophagy modulators, methods of preparation and uses thereof | 微境生物医药科技(上海)有限公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-3632903-B1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | WIGEN BIOMEDICINE TECH SHANGHAI CO LTD (CN) | 2023-10-11 | — | — | EP | disclosed |
| CN-111148740-B | Compounds useful as autophagy modulators, methods of preparation and uses thereof | 微境生物医药科技(上海)有限公司 | 2023-08-25 | — | — | CN | disclosed |
| CN-112521529-B | LED sensitive distyryl oxime ester photoinitiator and preparation and application thereof | 同济大学 | 2022-07-08 | — | — | CN | disclosed |
| US-11319303-B2 | Compound used as autophagy regulator, and preparation method therefor and uses thereof | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2022-05-03 | — | — | US | disclosed |
| US-11319303-B2 | Compound used as autophagy regulator, and preparation method therefor and uses thereof | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2022-05-03 | — | — | US | disclosed |
| CN-112521529-A | LED sensitive distyryl oxime ester photoinitiator and preparation and application thereof | 同济大学 | 2021-03-19 | — | — | CN | disclosed |
| US-20200190066-A1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2020-06-18 | — | — | US | disclosed |
| US-20200190066-A1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2020-06-18 | — | — | US | disclosed |
| CN-111148740-A | Compounds useful as autophagy modulators and methods of making and using the same | 微境生物医药科技(上海)有限公司 | 2020-05-12 | — | — | CN | disclosed |
| EP-3632903-A1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2020-04-08 | — | — | EP | disclosed |
| EP-1458707-B1 | New Indol-2-one derivatives | ASTRAZENECA AB (SE) | 2007-05-02 | — | — | EP | disclosed |
| US-7205314-B2 | Compounds for the treatment of dementia related diseases | ASTRAZENECA AB (SE) | 2007-04-17 | — | — | US | disclosed |
| US-20050065170-A1 | associated with the inhibition of glycogen synthase kinase-3, prevention and/or treatment of dementia related disease, Alzheimer's Disease etc.; example: 3-[6-(2-Methoxyethoxy)isoquinolin-1-yl]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | US | disclosed |
| US-6852731-B2 | Antiviral compounds | PFIZER (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY | 2004-12-02 | — | — | US | disclosed |
| EP-1472260-A2 | THIENO(3,2-B)PYRIDONES AS ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-03 | — | — | EP | disclosed |
| EP-1458707-A2 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003059878-A2 | THIENO (3, 2-B) PYRIDONES AS ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003053330-A2 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER’S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | ASTRAZENECA AB (SE) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319303-B2 | Compound used as autophagy regulator, and preparation method therefor and uses thereof | ATG7, SQSTM1, BECN1 | NPC1 231/4885RAB9A 130/4885TDP1 3746/4885 |
| US-20050065170-A1 | associated with the inhibition of glycogen synthase kinase-3, prevention and/or treatment of dementia related disease, Alzheimer's Disease etc.; example: 3-[6-(2-Methoxyethoxy)isoquinolin-1-yl]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile | GSK3A, GSK3B, PYGB | NPC1 1617/4885RAB9A 3755/4885TDP1 619/4885 |
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, IRF3, IFNAR1 | NPC1 254/4885RAB9A 1000/4885TDP1 704/4885 |
| US-20200190066-A1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | ATG7, SQSTM1, BECN1 | NPC1 231/4885RAB9A 130/4885TDP1 3746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.